论文部分内容阅读
目的:探究吡格列酮和二甲双胍对初诊2型糖尿病患者肠源性内毒素水平的影响。方法:选取初诊2型糖尿病患者105例,随机分为吡格列酮治疗组(52例)和二甲双胍治疗组(53例),以同期性别、年龄匹配的健康体检者42例作为对照组,治疗12周之后比较两组治疗前后肠源性内毒素及相关生化指标的变化情况。结果:治疗前,两治疗组的肠源性内毒素水平均显著高于对照组(P<0.05);吡格列酮治疗后,患者肠源性内毒素和hs-CRP水平均下降较为明显(P<0.01);而二甲双胍治疗后,仅hs-CRP水平显著下降,差异具有统计学意义(P<0.05),而肠源性内毒素下降不明显(P>0.05);但两种药物治疗后,肠源性内毒素水平仍高于对照组(P<0.01)。结论:吡格列酮可以降低初诊2型糖尿病患者的肠源性内毒素水平,而二甲双胍对肠源性内毒素的下降作用不明显。
Objective: To investigate the effects of pioglitazone and metformin on the levels of intestinal endotoxin in newly diagnosed type 2 diabetic patients. Methods: A total of 105 newly diagnosed type 2 diabetic patients were randomly divided into two groups: pioglitazone group (52 cases) and metformin group (53 cases). 42 cases of healthy subjects with the same gender and age were selected as control group. After 12 weeks The changes of intestinal endotoxin and related biochemical indexes before and after treatment were compared between the two groups. Results: Before treatment, the intestinal endotoxin levels in the two treatment groups were significantly higher than those in the control group (P <0.05). After the treatment with pioglitazone, the levels of intestinal endotoxin and hs-CRP decreased significantly (P <0.01 (P <0.05), but the decrease of intestinal endotoxin was not significant (P> 0.05). However, after treatment with metformin, the level of hs-CRP only decreased significantly, the difference was statistically significant The level of endotoxin was still higher than that of the control group (P <0.01). Conclusion: Pioglitazone can reduce the level of intestinal endotoxin in newly diagnosed type 2 diabetic patients, while metformin has no obvious effect on the decrease of intestinal endotoxin.